Better Health,
Brighter Future
Takeda to present 23 company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting
Takeda will present 14 abstracts in oncology and nine in hematology at the 2021 ASH Annual Meeting being held December 11-14, 2021. The highlights of data to be presented include:
Oncology
|
Abstract Number |
Title |
Session |
Hodgkin Lymphoma |
||
|
Use of Positron Emission Tomography in Patients With Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-center, Retrospective B-HOLISTIC Study |
Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I
Poster Presentation, December 11, 2021, 5:30 – 7:30 p.m. ET
Location: Hall B5 |
|
Chronic Myeloid Leukemia |
||
|
Post hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR-ABL1 level and Baseline Mutation Status in the OPTIC Trial |
Chronic Myeloid Leukemia: Clinical and Epidemiological: Mechanisms of resistance and expanded therapies
Oral Presentation, December 11, 2021, 4:00 – 5:30 p.m. ET
Location: B304-B305 |
|
|
Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) From the PACE and OPTIC Trials |
Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II
Poster Presentation, December 12, 2021, 6:00 – 8:00 p.m. ET
Location: Hall B5 |
|
Multiple Myeloma |
||
|
Efficacy and safety of oral ixazomib (Ixa), intravenous (IV) daratumumab (Dara), and IV/oral dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: results of the second interim analysis (IA2) of a phase 2 study |
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials
Poster Presentation, December 11, 2021, 5:30 – 7:30 p.m. ET
Location: Hall B5 |
|
|
Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM) |
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials
Poster Presentation, December 11, 2021, 5:30 – 7:30 p.m. ET
Location: Hall B5 |
|
|
Progression-free survival (PFS) according to the presence of adverse cytogenetic abnormalities in patients (pts) with multiple myeloma (MM) receiving ixazomib (ixa)-based vs placebo (pbo)-based therapy: A pooled analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 phase 3 studies |
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials
Poster Presentation, December 11, 2021, 5:30 – 7:30 p.m. ET
Location: Hall B5 |
|
|
Late vs early response and depth of response are associated with improved outcomes in newly diagnosed multiple myeloma (NDMM) patients (pts) treated with ixazomib-lenalidomide-dexamethasone (IRd) or placebo-lenalidomide-dexamethasone (pbo-Rd) in the phase 3 TOURMALINE-MM2 trial |
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials
Poster Presentation, December 12, 2021, 6:00 – 8:00 p.m. ET
Location: Hall B5 |
|
|
The INSURE study (INSIGHT MM, UVEA-IXA, REMIX): a pooled analysis of relapsed/refractory multiple myeloma (RRMM) patients (pts) treated with ixazomib-lenalidomide-dexamethasone (IRd) in routine clinical practice |
Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
Poster Presentation, December 12, 2021, 6:00 – 8:00 p.m. ET
Location: Hall B5 |
|
|
Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation |
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials
Poster Presentation, December 12, 2021, 6:00 – 8:00 p.m. ET
Location: Hall B5 |
|
|
Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE) |
Outcomes Research—Lymphoid Malignancies: Poster II
Poster Presentation, December 12, 2021 6:00 - 8:00 p.m. ET
Location: Hall B5 |
|
|
Modakafusp alfa (TAK-573), an immunocytokine, shows clinical activity in patients with relapsed/refractory multiple myeloma; updated results from a first-in-human phase 1 study
|
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma
Oral Presentation, December 13, 2021, 6:15 – 7:45 p.m. ET
Location: A411-A412 |
|
Higher-Risk Myelodysplastic Syndromes |
||
|
Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20–30% Marrow Blasts: The Randomized Phase 3 Panther Trial (NCT03268954)
|
Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of High Risk Myelodysplastic Syndrome
Oral Presentation, December 11, 2021, 2:00 – 3:30 p.m. ET
Location: B207-B208 |
|
Pipeline |
||
|
Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination With Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma |
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II
Poster Presentation, December 12, 2021, 6:00 – 8:00 p.m. ET
Location: Hall B5 |
|
|
TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data |
Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II
Poster Presentation, December 12, 2021, 6:00 – 8:00 p.m. ET
Location: Hall B5 |
|
Hematology
|
Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia: Interim Results from an Open-Label Multicenter Clinical Trial |
Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III
Poster Presentation, Monday, December 13, 2021: 6:00 PM-8:00 PM ET
Location: Hall B5 |
|
|
Prophylactic Treatment with Rurioctocog Alfa Pegol Results in a Dose-Dependent Normalization of Biomarkers of Joint Health in Severe Hemophilia a: An Exploratory Analysis from the Propel Study |
Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II
Poster Presentation, Sunday, December 12, 2021: 6:00 PM-8:00 PM ET
Location: Hall B5 |
|
|
A Real-world Study of Pre-Post Annualized Bleed Rates and All Cause Costs Among Non-inhibitor Patients with Hemophilia A Switching from FVIII Prophylaxis to Emicizumab |
Outcomes Research—Non-Malignant Conditions: Poster II
Poster Presentation, Sunday, December 12, 2021: 6:00 PM-8:00 PM ET
Location: Hall B5 |
|
|
138 (Supplement 19) |
Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura: Design of a Phase 3b Open-Label Continuation Study of Prophylactic and On-demand Treatment |
Accepted for online publication only |
|
Recombinant ADAMTS13 for Patients with Sickle Cell Disease: Design of a Phase 1 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics study |
Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster III
Poster Presentation, Monday, December 13, 2021: 6:00 PM-8:00 PM ET
Location: Hall B5 |
|
|
Rurioctocog alfa pegol use in immune tolerance induction: Interim results from an open-label multicenter clinical trial in previously untreated patients with severe hemophilia A |
Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III
Poster Presentation, Monday, December 13, 2021: 6:00 PM-8:00 PM ET
Location: Hall B5 |
|
|
Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study |
Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III
Poster Presentation, Monday, December 13, 2021: 6:00 PM-8:00 PM ET
Location: Hall B5 |
|
|
Exposure-response relationship between von Willebrand factor (VWF) activity and bleeding events following prophylaxis with recombinant VWF (rVWF, vonicog alfa) in patients with severe von Willebrand disease (VWD) |
Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II
Poster Presentation, Sunday, December 12, 2021: 6:00 PM-8:00 PM ET
Location: Hall B5 |
|
| Abstract 2109
|
Recombinant porcine factor VIII in patients with congenital hemophilia a with inhibitors undergoing surgery: Phase 3, multicenter, single arm, open-label study |
Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II Poster Presentation, Location: Hall B5 |